TL1A Genotype Screening for Personalized IBD Treatment Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory, fibrostenotic, and fibrotic diseases like inflammatory bowel disease (IBD) are inadequate, with many patients not responding to existing therapies, leading to disease worsening and invasive surgeries, and there is a lack of personalized medicine approaches to identify suitable therapeutic interventions.
Innovation Solution
A method involving the use of a Predictive Response Index (PRI) based on genetic polymorphisms to select patients for treatment with a TL1A inhibitor, which predicts a positive therapeutic response with a positive predictive value of at least 29%, by calculating a Response Probability Score (RPS) using statistical algorithms and genetic data.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing anti-inflammatory therapies (steroids and TNF inhibitors) are used as first line treatment, then treatment coverage is provided, but a significant number of patients experience lack of response or loss of response, leading to disease worsening
Solution Approach 1:
The patent performs genetic testing and calculates a Predictive Response Index (PRI) before initiating TL1A inhibitor treatment to identify patients most likely to respond. This preliminary action prevents ineffective treatment administration and improves overall therapeutic response rates by selecting appropriate candidates in advance.
Solution Approach 2:
The patent applies personalized treatment by targeting a specific patient subgroup (those with high PRI scores indicating likely response to TL1A inhibition) rather than applying uniform treatment to all IBD patients. This localized approach improves reliability for the target population while acknowledging heterogeneity in disease response.
2Reliability
If surgery (structureplasty or resection) is performed on patients who do not respond to first line therapies, then disease progression is halted, but invasive procedures cause post-operative risks including anastomotic leak, infection, and bleeding
Solution Approach 1:
The patent introduces TL1A inhibitors as an intermediate therapeutic option between failed first-line therapies and invasive surgery. This intermediary treatment addresses disease progression in patients who do not respond to conventional therapies while avoiding the harmful effects of surgical intervention, thereby reducing post-operative complications.
Solution Approach 2:
The patent performs preliminary genetic screening to identify patients who are likely to respond to TL1A inhibitors before administering the treatment. This ensures that patients who might benefit from avoiding surgery are correctly identified and treated with the less invasive biologic therapy, preventing the need for high-risk surgical procedures.
3Measurement precision
If personalized medicine approaches are implemented to identify suitable therapeutic interventions, then treatment precision is improved, but there is currently a lack of available personalized therapies and methodologies
Solution Approach 1:
The patent segments the IBD patient population into distinct subgroups based on their genetic profiles and predicted response to TL1A inhibition. By dividing patients into those likely to respond (high PRI) and those unlikely to respond (low PRI), the system achieves precise patient selection without requiring overly complex treatment protocols for the entire population.
Solution Approach 2:
The patent transforms complex genetic data into a simplified, actionable parameter - the Predictive Response Index (PRI) score. This parameter transformation converts multiple genetic polymorphisms and their interactions into a single metric that guides treatment decisions, reducing the perceived complexity while maintaining measurement precision.
4Productivity
If TL1A inhibitors are administered without patient selection, then treatment availability is maximized, but the positive predictive value of therapeutic response remains uncertain and resources may be wasted on non-responders
Solution Approach 1:
The patent performs preliminary genetic testing and PRI calculation before administering TL1A inhibitors to ensure patients are selected based on their likelihood of response. This preliminary screening maintains treatment accessibility for appropriate patients while improving response predictability by excluding those unlikely to benefit.
Solution Approach 2:
The patent uses genetic polymorphism data and PRI scores as feedback mechanisms to guide treatment decisions. This feedback system allows clinicians to predict therapeutic response before treatment initiation, optimizing the balance between treatment accessibility and response reliability by directing therapy to patients most likely to respond.
Data Source
AI summary
Provided are methods, systems, and kits for selecting a subject for treatment with an inhibitor of Tumor necrosis factor-like cytokine 1A (TL1A) activity or expression based on a presence of one or more genotypes associated with a positive therapeutic response to the inhibitor of TL1A. Also provided are methods, systems and kits for detecting the one or more genotypes described herein.